ライフサイエンスコーパス: vancomycin-resistant enterococci

1 oft-tissue infections, and infections due to vancomycin-resistant enterococci.

2 und in a subset of 875 recent US isolates of vancomycin-resistant enterococci.

3 - and vancomycin-resistant Staphylococci and vancomycin-resistant Enterococci.

4 There were no vancomycin-resistant enterococci.

5 tions such as relapses and infections due to vancomycin-resistant enterococci.

6 A and B two-component regulatory switches in vancomycin-resistant enterococci.

7 omologous D-Ala:D-lactate ligase produced by vancomycin-resistant enterococci.

8 aureus, vancomycin-resistant S. aureus, and vancomycin-resistant enterococci.

9 s used for molecular epidemiologic typing of vancomycin-resistant enterococci.

10 3%) environmental cultures were positive for vancomycin-resistant enterococci.

11 mug/mL), including enhanced potency against vancomycin-resistant enterococci.

12 ed off-label to treat patients infected with vancomycin-resistant enterococci.

13 stance to daptomycin during the treatment of vancomycin-resistant enterococci.

14 reus, vancomycin-intermediate S. aureus, and vancomycin-resistant Enterococci.

15 ureus, vancomycin-intermediate S. aureus and vancomycin-resistant enterococci.

16 with linezolid for bloodstream infections by vancomycin-resistant enterococci.

17 cocci, macrolide-resistant streptococci, and vancomycin-resistant enterococci.

18 etection of gastrointestinal colonization by vancomycin-resistant enterococci.

19 ese patients may help decrease the spread of vancomycin-resistant enterococci.

20 i and to assess molecular characteristics of vancomycin-resistant enterococci, 157 clinical blood iso

21 trol policies to prevent the transmission of vancomycin-resistant enterococci (22 of 25 [88 percent]

22 f the long-term care facilities screened for vancomycin-resistant enterococci (26 of 28 in 1998 [93 p

23 The VanA ligase of vancomycin-resistant enterococci, a D-Ala-D-lactate deps

24 phalosporin-resistant enterobacteriaceae and vancomycin-resistant enterococci (acquired antibiotic re

25 Vancomycin-resistant enterococci and Klebsiella pneumoni

26 ive against Gram-positive bacteria including vancomycin-resistant enterococci and methicillin-resista

27 th of antibiotic resistant superbugs such as vancomycin-resistant Enterococci and Staphylococci has b

28 h hydrophobic side chains are active against vancomycin-resistant enterococci and vancomycin-resistan

29 s aeruginosa, and vancomycin-susceptible and vancomycin-resistant enterococci and with 193 perianal s

30 -lactamase-producing Gram-negative bacteria, vancomycin-resistant enterococci, and Clostridium diffic

31 study of gastrointestinal colonization with vancomycin-resistant enterococci, and compared infection

32 including meticillin-resistant Staph aureus, vancomycin-resistant enterococci, and penicillin-resista

33 us aureus, coagulase-negative staphylococci, vancomycin-resistant enterococci, and resistance to thir

34 ococci; the number of days to acquisition of vancomycin-resistant enterococci; and other measurements

35 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci), antifungal socks (whi

36 Vancomycin-resistant enterococci are a major cause of no

37 d, 900-bed, urban teaching hospital in which vancomycin-resistant enterococci are endemic.

38 l intensive care unit of a hospital in which vancomycin-resistant enterococci are endemic.

39 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci as well as hemolytic ac

40 study of 51 patients who were colonized with vancomycin-resistant enterococci, as evidenced by the pr

41 The overall prevalence of vancomycin-resistant enterococci at 30 facilities that p

42 control practices and screening policies for vancomycin-resistant enterococci at the acute care and l

43 A rapid protocol for subtyping vancomycin-resistant enterococci by pulsed-field gel ele

44 meticillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, C difficile, and multi

45 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci clinical isolates and i

46 ities that had had at least one patient with vancomycin-resistant enterococci declined from 15 in 199

47 e of D-serine for peptidoglycan synthesis in vancomycin-resistant enterococci expressing the VanC phe

48 tibacterial assays employing a unique set of vancomycin-resistant Enterococci faecalis and Enterococc

49 ncomycin-sensitive Staphylococcus aureus and vancomycin-resistant Enterococci faecalis as well as the

50 her derivative of vancomycin aglycon against vancomycin-resistant Enterococci faecalis previously rep

51 Two isolates among vancomycin-resistant enterococci from the greater Housto

52 inst methicillin-resistant staphylococci and vancomycin-resistant enterococci has been purified, and

53 Colonization and infection with vancomycin-resistant enterococci have been associated wi

54 ceptional growth inhibitory activity against vancomycin-resistant Enterococci (IC50 40 nM), >270-fold

55 screening and infection-control policies for vancomycin-resistant enterococci in 1998 and 1999.

56 es only in preventing rectal colonization by vancomycin-resistant enterococci in a medical intensive

57 We examined the density of vancomycin-resistant enterococci in stool during and aft

58 When the density of vancomycin-resistant enterococci in stool was at least 4

59 For patients with vancomycin-resistant enterococci in stool, treatment wit

60 The advent of vancomycin-resistant enterococci in the 1990s and the th

61 can reduce or eliminate the transmission of vancomycin-resistant enterococci in the health care faci

62 21 (23.9%) in the glove-only group acquired vancomycin-resistant enterococci in the medical intensiv

63 on was sought in assessing the prevalence of vancomycin-resistant enterococci in the region's facilit

64 oratories conducting active surveillance for vancomycin-resistant enterococci in three San Francisco

65 evention received a report of an outbreak of vancomycin-resistant enterococci in which 31 of 84 (36.9

66 Risk factors for acquisition of vancomycin-resistant enterococci induced length of stay

67 ains or hospitals in which the prevalence of vancomycin-resistant enterococci is low.

68 s and Enterococcus gallinarum (intrinsically vancomycin-resistant enterococci [IVRE]) from Enterococc

69 All 465 (100%) vancomycin-resistant enterococci (MIC > or = 32 microgra

70 p and 13 (14.8%) in the glove-only group had vancomycin-resistant enterococci on admission to the med

71 If the total number of vancomycin-resistant enterococci patients in the ICU wer

72 b-lacZ fusions report on expression from the vancomycin-resistant enterococci promoters of the type A

73 vanHAX are orthologous to genes found in vancomycin-resistant enterococci that encode enzymes pre

74 The number of patients becoming colonized by vancomycin-resistant enterococci; the number of days to

75 mice that have intestinal colonization with vancomycin-resistant enterococci, these agents promote h

76 ata from an interrupted time-series study of vancomycin-resistant enterococci transmission in a hemat

77 ising improvement of its bioactivity against vancomycin-resistant enterococci (Van A and Van B phenot

78 In pathogenic vancomycin-resistant enterococci, vanX is part of a five

79 ent-specific risk factors for acquisition of vancomycin-resistant enterococci (VRE) among hospitalize

80 The transmission dynamics of vancomycin-resistant enterococci (VRE) and factors contr

81 We analyzed surveillance cultures for vancomycin-resistant enterococci (VRE) and methicillin-r

82 to selective enrichment broth for detecting vancomycin-resistant enterococci (VRE) and multidrug-res

83 gy laboratory to determine the prevalence of vancomycin-resistant enterococci (VRE) and multidrug-res

84 Surveillance cultures for vancomycin-resistant enterococci (VRE) and subsequent ch

85 se of potential postpartum infections due to vancomycin-resistant enterococci (VRE) and the possible

86 ctively analyzed risk factors and outcome of vancomycin-resistant enterococci (VRE) and vancomycin-se

87 erococcus faecalis bacteremia caused by both vancomycin-resistant enterococci (VRE) and vancomycin-su

88 Vancomycin-resistant enterococci (VRE) are an important

89 Vancomycin-resistant enterococci (VRE) are common hospit

90 Vancomycin-resistant enterococci (VRE) are increasingly

91 Vancomycin-resistant enterococci (VRE) are increasingly

92 Vancomycin-resistant enterococci (VRE) are nosocomial pa

93 Surveillance cultures for vancomycin-resistant enterococci (VRE) are time-consumin

94 Treatment options for vancomycin-resistant enterococci (VRE) bloodstream infec

95 ta in the colon inhibit the establishment of vancomycin-resistant enterococci (VRE) colonization by d

96 concentrations, did not promote significant vancomycin-resistant enterococci (VRE) colonization.

97 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) due to the scope

98 Vancomycin-resistant enterococci (VRE) escape the bacter

99 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) for extended peri

100 r (BBL, Sparks, Md.) for direct detection of vancomycin-resistant enterococci (VRE) from 894 perianal

101 Xpert vanA assay for routine surveillance of vancomycin-resistant enterococci (VRE) from rectal swabs

102 ug/ml vancomycin (BEAV) for the isolation of vancomycin-resistant enterococci (VRE) from stool specim

103 The treatment of infections caused by vancomycin-resistant enterococci (VRE) has become an imp

104 incidence of colonization and infection with vancomycin-resistant enterococci (VRE) has increased dra

105 Vancomycin-resistant enterococci (VRE) have emerged as n

106 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) have now arisen a

107 rs were compared for their ability to detect vancomycin-resistant enterococci (VRE) in 750 stool spec

108 ve E. faecium, which implies that control of vancomycin-resistant enterococci (VRE) in hospitals also

109 -resistant Staphylococcus aureus (EMRSA) and vancomycin-resistant enterococci (VRE) in hospitals in E

110 Active screening for vancomycin-resistant enterococci (VRE) in rectal and sto

111 As infection with vancomycin-resistant enterococci (VRE) increases in hosp

112 he identification of patients colonized with vancomycin-resistant enterococci (VRE) is central to the

113 Vancomycin resistance in vancomycin-resistant enterococci (VRE) is due to an alte

114 that a method of performing surveillance for vancomycin-resistant enterococci (VRE) is to screen spec

115 e gastrointestinal tracts are colonized with vancomycin-resistant enterococci (VRE) may serve as a re

116 esistant Staphylococcus aureus (MRSA) and/or vancomycin-resistant enterococci (VRE) on at least 1 occ

117 Vancomycin-resistant enterococci (VRE) recently have eme

118 biquitous on plasmids isolated from clinical vancomycin-resistant enterococci (VRE) strains.

119 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) that are known to

120 Vancomycin resistance is conferred upon vancomycin-resistant enterococci (VRE) through the repla

121 trains to the establishment of endemicity of vancomycin-resistant enterococci (VRE) were determined.

122 the Massachusetts General Hospital from whom vancomycin-resistant enterococci (VRE) were isolated fro

123 Among our patient population, more vancomycin-resistant enterococci (VRE) were recovered wi

124 typic variation and stability of isolates of vancomycin-resistant enterococci (VRE) were studied to d

125 tant Staphylococcus aureus (MRSA) as well as vancomycin-resistant enterococci (VRE) with minimum inhi

126 tiresistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), among patients i

127 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and ceftazidime-

128 , as well as glycopeptides effective against vancomycin-resistant enterococci (VRE), and fluoroquinol

129 vancomycin (BEAV) agar (84.8%) for detecting vancomycin-resistant enterococci (VRE), and the results

130 With increasing prevalence of vancomycin-resistant enterococci (VRE), appropriate anti

131 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), has reached a cr

132 ibiotic-resistant bacterial species, such as vancomycin-resistant enterococci (VRE), necessitates the

133 anA/vanB DNA hybridization assay to identify vancomycin-resistant enterococci (VRE), was evaluated fo

134 ulty in detecting intermediate and low-level vancomycin-resistant enterococci (VRE).

135 agar plates as negative or "nonnegative" for vancomycin-resistant enterococci (VRE).

136 omycin per ml and evaluated for isolation of vancomycin-resistant enterococci (VRE).

137 epted method for detecting colonization with vancomycin-resistant enterococci (VRE).

138 to develop an antimicrobial peptide against vancomycin-resistant enterococci (VRE).

139 ater than 1000-fold was demonstrated against vancomycin-resistant Enterococci (VRE).

140 in antimicrobial potency (200-fold) against vancomycin-resistant Enterococci (VRE).

141 nsive care unit for rectal colonization with vancomycin-resistant enterococci (VRE).

142 han vancomycin and has activity against many vancomycin-resistant enterococci (VRE).

143 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE).

144 t contribute to the transmission dynamics of vancomycin-resistant enterococci (VRE).

145 in-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococci (VRE).

146 treatment of patients with stool carriage of vancomycin-resistant enterococci (VRE).

147 In 1996, the dominant (43%) strain of vancomycin-resistant enterococci (VRE; type A) at Massac

148 rococcal bloodstream infection (BSI; 22 with vancomycin-resistant enterococci [VRE] and 61 with vanco

149 n-resistant Staphylococcus aureus [MRSA] and vancomycin-resistant enterococci [VRE]) or rapid screeni

150 (95 percent), high-density colonization with vancomycin-resistant enterococci was maintained (mean [+

151 All 36 vancomycin-resistant enterococci were detected by the Ph

152 Nineteen types of vancomycin-resistant enterococci were documented by puls

153 In late 1996, vancomycin-resistant enterococci were first detected in

154 hicillin-resistant Staphylococcus aureus, or vancomycin-resistant enterococci were included.

155 ties, the risk factors for colonization with vancomycin-resistant enterococci were prior hospitalizat

156 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci, without affecting the

157 mutant subsequently resulted in clearance of vancomycin-resistant enterococci, without plasmid transf